Alnylam Pharmaceuticals, Inc. vs Barrick Gold Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.03B), while Barrick Gold Corp trades at $40.8 (market cap $68.49B). The key difference: Barrick Gold Corp is far larger — about 2.4× Alnylam Pharmaceuticals, Inc.'s market cap, and Barrick Gold Corp pays a 1.71% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | B | |
|---|---|---|
Market Cap | $29.03B | $68.49B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $52.97 |
52-Week Low | $205.48 | $23.50 |
Enterprise Value | $26.99B | $66.08B |
Dividend Yield | — | 1.71% |
Trailing returns across standard periods
Latest headlines on both assets
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →Barrick Gold Corp is one of the world's largest gold producers, operating mines in North America, South America, Australia, and Africa. The company segments consist of nine gold mines namely Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, and Bulyanhulu. It generates maximum revenue from the Carlin mine segment. Geographically, it derives a majority of revenue from the United States.
Read more on B →